Efficacy of mosapride versus domperidone in the treatment of functional dyspepsia and its effects on gastric motility indexes and gastrointestinal hormone levels / 中国基层医药

ABSTRACT

Objective:To investigate the efficacy of mosapride versus domperidone in the treatment of functional dyspepsia and its effects on gastric motility indexes and gastrointestinal hormone levels. Methods:Ninety-four patients with functional dyspepsia who received treatment in Huzhou Linghu People's Hospital between May 2019 and May 2021 were included in this study. They were randomly assigned to undergo treatment with either domperidone (control group, n = 47) or mosapride (study group, n = 47). Efficacy was compared between the two groups. Results:Total response rate in the study group was significantly higher than that in the control group ( χ2 = 5.04, P = 0.025). After medication, motilin, plasma leptin and corticotropin-releasing hormone in the study group were (184.22 ± 25.36) μg/mL, (18.57 ± 2.44) μg/L, (7.21 ± 1.14) pg/mL, respectively, which were superior to those in the control group [(111.25 ± 21.00) μg/mL, (15.41 ± 2.28) μg/L, (9.02 ± 1.32) μg/mL, t = 15.19, 6.48, 16.23, P < 0.001, < 0.001, < 0.001]. After medication, cholecystokinin, somatostatin, vasoactive intestinal peptide and gastrin levels in the study group were (45.36 ± 5.12) ng/L, (5.48 ± 1.25) ng/L, (86.35 ± 12.11) pg/mL, and (105.24 ± 12.05) ng/L, respectively, which were significantly superior to those in the control group [(50.21 ± 6.18) ng/L, (7.01 ± 0.98) ng/L, (98.75 ± 14.18) pg/mL and (97.35 ± 11.48) ng/L, t = 4.14, 6.60, 4.55, 3.25, P < 0.001, < 0.001, < 0.001, < 0.002]. The recurrence rate in the study group was significantly lower than that in the control group (2.13% vs. 27.66%, χ2 = 4.66, P = 0.031). The incidence of adverse reactions in the study group was significantly lower than that in the control group (14.89% vs. 34.04%, χ2 = 10.80; P = 0.001). Conclusion:Mosapride has a better therapeutic effect on functional dyspepsia, exhibits a greater effect on improving gastric motility indexes and gastrointestinal hormone levels, and leads to a lower incidence of recurred functional dyspepsia than domperidone. Therefore, mosapride for treatment of functional dyspepsia deserves clinical promotion.